Company intelligence / Profile preview

Alga Biosciences

San Francisco, California, United Statesalga.bio ↗

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Alga Biosciences has developed an algae-derived feed additive that reduces methane emissions from cattle by up to 97%, with additional benefits of decreasing required feed intake. The product targets the agricultural sector and aims for rapid, scalable climate impact. No traditional clinical results as the product addresses environmental outcomes rather than medical endpoints.

Modalities: Feed additive (Algae-based feed supplement)
Industry: Non-Drug Biotech

Partnerships

Collaborations with cattle owners, ranchers, and scientists; no major pharma partners reported

Beyond the preview

Go deeper on Alga Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alga Biosciences.

Explore the full profile